Urinary Excretion of Pregnanetriol and Δ5-Pregnenetriol in Two Forms of Congenital Adrenal Hyperplasia
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Evaluation of Deficiency of 21 -Hydroxylation in Patients with Congenital Adrenal Hyperplasia 0
Arch Dis Child: first published as 10.1136/adc.43.230.410 on 1 August 1968. Downloaded from Arch. Dis. Childh., 1968, 43, 410. Evaluation of Deficiency of 21 -hydroxylation in Patients with Congenital Adrenal Hyperplasia 0. M. GALAL, B. T. RUDD, and N. M. DRAYER From the Institute of Child Health, University of Birmingham Congenital adrenal hyperplasia can manifest therapy in these 13 children started within the first 3 itself in a variety of clinical and biochemical weeks of life. abnormalities (Bongiovanni and Root, 1963). The In addition to the 18 patients with congenital adrenal salt-losing tendency in some of these patients can hyperplasia, 3 children with shortness of stature and 3 with early signs of puberty were given ACTH to be due to the absence of specific enzymes: dehydro- investigate their adrenal function. None of these genases or hydroxylases (Bongiovanni and Root, patients had received steroids and all had normal free 1963; Ulick et al., 1964; Visser and Cost, 1964). cortisol and 17-hydroxycorticosteroid urinary excretion In addition to the impaired production of certain rates. The age and sex of the patients in the 3 groups steroids, antagonism by steroids or other compounds and details of the steroid therapy are listed in Table I. could, theoretically, account for the salt-losing tendency (Neher, Meystre, and Wettstein, 1959; ACTH test. Twenty-four hour urine collections Jacobs et al., 1961). were obtained before and during ACTH stimulation. The purpose ofthis study was to discover whether, ACTH gel (Organon) was given intramuscularly at a copyright. despite the continuation of steroid therapy, stimula- dose of 20 I.U. -
400 We Have Studied Six Infants and Young Children with Hyper
400 ABSTRACTS We have studied six infants and young children with hyper- ml plasma sample has been evaluated for the rapid (4—6 hr) diag- thyroidism whose clinical course differs from the few reports of nosis of CAH. Pet ether, benzene and methylene chloride extracts others. Neonatal and early childhood hyperthyroidism are usually of plasma are quantitated by competitive protein binding using thought of as separate, rare, and transient disorders seldom re- 17-hydroxyprogesterone (17-OHP), 11-deoxycortisol (cmpd S), quiring long term treatment. 1) Our cases have not been tran- and cortisol standards, respectively, for comparison. The observed sient: 2) they have occurred in families with a high incidence of plasma steroid concentrations are expressed as a ratio of adult Graves disease. "17-OHP" + "cmpd S" to "cortisol" since comparison of ratios, Four were born with Graves disease. Three continue to be rather than absolute values, has been found to differentiate nor- hyperthyroid at ages 1, 5, and 6 years. Two developed Graves mals from patients more clearly. disease at ages 3 and 8 years and continue on anti-thyroid medi- Plasma samples have been obtained from six normal children cation. Graves disease occurred in five of the six mothers and aged 4 days-7 yrs following administration of ACTH, from six was apparent during gestation in four. The sixth mother, mother adults with 11-hydroxylation impaired by the administration of of a neonatal case, has never had overt Graves disease, but female metyrapone, and from three children aged 11 mos, 6 yrs and 8 members of four generations have had Graves disease. -
Endocrinology Test List Endocrinology Test List
For Endocrinologists Endocrinology Test List Endocrinology Test List Extensive Capabilities Managing patients with endocrine disorders is complex. Having access to the right test for the right patient is key. With a legacy of expertise in endocrine laboratory diagnostics, Quest Diagnostics offers an extensive menu of laboratory tests across the spectrum of endocrine disorders. This test list highlights the extensive menu of laboratory diagnostic tests we offer, including highly specialized tests and those performed using highly specific and sensitive mass spectrometry detection. It is conveniently organized by glandular function or common endocrine disorder, making it easy for you to identify the tests you need to care for the patients you treat. Comprehensive Care Quest Diagnostics Nichols Institute has been pioneering state-of-the-art endocrine testing for over four decades. Our commitment to innovative diagnostics and our dedication to quality and service means we deliver solutions that enable you to make informed clinical decisions for comprehensive patient management. We strive to remain at the forefront of innovation in endocrine testing so you can deliver the highest level of patient care. Abbreviations and Footnotes NDM, neonatal diabetes mellitus; MODY, maturity-onset diabetes of the young; CH, congenital hyperinsulinism; MSUD, maple syrup urine disease; IHH, idiopathic hypogonadotropic hypogonadism; BBS, Bardet-Biedl syndrome; OI, osteogenesis imperfecta; PKD, polycystic kidney disease; OPPG, osteoporosis-pseudoglioma syndrome; CPHD, combined pituitary hormone deficiency; GHD, growth hormone deficiency. The tests highlighted in green are performed using highly specific and sensitive mass spectrometry detection. Panels that include a test(s) performed using mass spectrometry are highlighted in yellow. For tests highlighted in blue, refer to the Athena Diagnostics website (athenadiagnostics.com/content/test-catalog) for test information. -
Comprehensive Urinary Hormone Assessments
ENDOCRINOLOGY Complete Hormones – Analytes Comprehensive Urinary Hormone Assessments Urinary Pregesterones Urinary Glucocorticoids Urinary Androgens Urinary Estrogens Pregnanediol Cortisol, Free Testosterone Estrone Pregnanetriol Total 17-Hydroxy-corticosteroids Dehydroepiandrosterone (DHEA) Estradiol allo-Tetrahydrocortisol, a-THF Total 17-Ketosteroids Estriol Tetrahydrodeoxycortisol Androsterone 2-Hydroxyestrone Tetrahydrocortisol, THF Etiocholanolone 2-Methoxyestrone Tetrahydrocortisone, THE 11-Keto-androsterone 4-Hydroxyestrone 17-Hydroxysteriods, Total 11-Keto-etiocholanolone 4-Methoxyestrone Pregnanetriol 11-Hydroxy-androsterone 16α-Hydroxyestrone 11-Hydroxy-etiocholanolone 2-Hydroxy-estrone:16α-Hydroxyestrone ratio 2-Methoxyestrone:2-Hydroxyestrone ratio CLINICIAN INFORMATION 4-Methoxyestrone:4-Hydroxyestrone ratio ADVANCING THE CLINICAL UTILITY OF URINARY HORMONE ASSESSMENT Specimen Requirements Complete Hormones™ is Genova’s most comprehensive • 120 ml aliquot, refrigerated until shipped, urinary hormone profile, and is designed to assist with the from either First Morning Urine or 24-Hour clinical management of hormone-related symptoms. This profile Collection Why Use Complete Hormones? assesses parent hormones and their metabolites as well as key metabolic pathways, and provides insight into the contribution Hormone testing is an effective tool for assessing Related Profiles: that sex hormones may have in patients presenting with and managing patients with hormone- related symptoms. This profile supports: • Male Hormonal Health™ -
Four Clinical Variants of Congenital Adrenal Hyperplasia
Arch Dis Child: first published as 10.1136/adc.39.203.66 on 1 February 1964. Downloaded from Arch. Dis. Childh., 1964, 39, 66. FOUR CLINICAL VARIANTS OF CONGENITAL ADRENAL HYPERPLASIA BY W. HAMILTON and M. G. BRUSH From the University Department of Child Health and the Royal Hospitalfor Sick Children, Glasgow, and the University Department of Steroid Biochemistry and the Royal Infirmary, Glasgow (RECEIVED FOR PUBLICATION AUGUST 26, 1963) Three clinical types of congenital adrenogenital Case Reports virilism due to adrenal hyperplasia have now been Case 1. This child, born January 27, 1954, was of well defined. These are simple virilization, viriliza- ambiguous sex having a curved phallus with an opening tion with excessive sodium loss and danger to life at the tip. Both this and another opening on the peri- and virilization combined with hypertension. Clini- neum admitted a probe to a depth of 1 cm. The scrotum cal subvariants have also been described in asso- was bifid and the testes were not palpated. ciation with hypoglycaemia (White and Sutton, When 5 weeks of age, a skin biopsy and buccal smear examined for sex chromatin indicated that the child was 1951; Wilkins, Crigler, Silverman, Gardner and female. The urinary 17-oxosteroids were reported as Migeon, 1952), with periodic fever (Gonzales and 0 4 mg. per day. When 2 years of age the perineum Gardner, 1956; Gardner and Migeon, 1959) and with was opened up in the midline and the urethral and the late onset of sodium loss (Cara and Gardner, vaginal orifices were found to open on to a small vestibule. -
CA SKLAR and RA ULSTROM, University of Minnesota
C.A. SKLAR and R.A. ULSTROM, University of Minnesota U. Vetter, J. Homoki, W.M. Teller 130 Hospitals, Minneapolis, Minnesota 133 Department of Pediatrics, University of Ulm, FRG Growth Hormone and Adrenal Androgen Secretion The effect of growth hormone (GH) on adrenal androgen secretion 17a-Hydroxylase-deficiency with unimpaired aldosterone formation was assessed in 7 patients (5 males, 2 females) with GH deficiency in a male but normal ACTH-cortisol function. Patients ranged in age from Case report: This is the first report of a male neonate with 9 3/12-14 8/12 years. Plasma concentrations of dehydroep!androst 17a-hydroxylase deficiency with micropenis, hypospadia and normal erone (OHEA), its sulfate (OHEA-S) and androstenedione A), as aldosterone secretion. Diagnosis was based on elevated excretion well as urinary 17-ketosteroids and free cortisol were determined of PD, DOC, TH-DOC, THB, allo-THB and decreased excretion of before, during short-term (2U/dx3) and after long-term (6 months) Cortisol, 11-desoxy-cortisol, THF, THE and testosterone. Serum treatment with GH. The baseline, pretreatment plasma levels of levels of ACTH, LH, FSH, DOC were elevated whereas cortisol, OHEA-S were appropriate for the indiv!duals' degree of skeletal testosterone and PRA were decreased. Serum levels and urinary maturation, whereas plasma OHEA and Awere undetectable «42ng/dl excretion of aldosterone were normal. and< 27ng/dl, respectively) in 5/7 subjects. No significant Discussion: 17a-hydroxylase deficiency is a rare disorder of change was noted in the plasma androgen values or in the urinary steroid metabolism. The clinical pattern in adults presents 17-ketosteroid and free cortisol concentrations during the short with hypokalaemic hypertension associated with metabolic term administration of GH. -
Exchangeable Sodium and Aldosterone Secretion in Children with Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency
Pediat. Res. 4: 145-156 (1970) Aldosterone 21-hydroxylase congenital 11-ketopregnanetriol adrenal pregnanetriol hyperplasia sodium metabolism Exchangeable Sodium and Aldosterone Secretion in Children with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency B. LORAS, F. HAOUR and J. BERTRAND[34] I.N.S.E.R.M., Unitt de Recherches Endocriniemes et Mttaboliques chez l'Enfant, HGpital Debrousse, Lyon, France Extract Aldosterone secretion rates (ASR) and exchangeable body sodium (Na,) have been measured simul- taneously in 25 cases of congenital adrenal hyperplasia (CAH) with and without salt loss, both during normal and during low salt intake. The degree of 21 -hydroxylase deficiency was assessed from the cortisol secretion rate (CSR) and urinary excretion of pregnanetriol and 11-ketopregnanetriol. In cases with salt loss, the sodium equilibrium was unstable, even with optimum treatment and increased dietary salt intake. Clinical evidence of salt-losing crisis appeared when 15-25% of Na, was lost. In these subjects, a parallel decrease in ASR and CSR usually occurred. The ASR were somewhat elevated in the nonsalt-losing form. Speculation A salt-excreting factor is probably present in CAH, even in the nonsalt-losing form, since the ASR is raised, while the Na, remains normal. Salt loss due to 21-hydroxylase deficiency decreases with age. This appears to be due to modifica- tions in the distribution of body sodium and to an absolute increase in the dietary salt intake rather than to modifications in adrenal secretion. Introduction between aldosterone production and disordered so- dium balance. Sodium levels in plasma and sodium About one-third of all cases of congenital adrenal excretion in urine, as well as the values for exchange- hyperplasia (CAH) due to 21-hydroxylase deficiency able sodium, have been measured in different situa- present with a salt-losing syndrome 1321. -
Endocrinology Assessments
2013 Edition Endocrinology Assessments PRODUCT LINE GUIDE THE GENOVA DIAGNOSTICS Advantage Our comprehensive line of assessments for personalized treatment & prevention of chronic disease: • Provides Fully Licensed and Certified Laboratory Services • Saves Practitioner Time with Easy-to-Read Test Results • Features Rapid Turnaround • Includes Support for Practitioner and Patient • Offers Patient and Practitioner Billing Options Visit us anytime on the web at www.GDX.net or call 800-522-4762 Monday through Friday, 8:30 am to 6:30 pm (Eastern Time) to order tests or more information about our services. ACCREDITATION Genova Diagnostics is fully licensed federally under Clinical Laboratory Improvement Amendments (CLIA) and certified by Medicare (all states), and by New York State. TABLE OF CONTENTS Endocrinology Product Line Guide for Genova Diagnostics 2-5 Steroidogenic Pathways Chart __________________________________18 Essence Hormone Tests ____________ First Morning Void vs. 24-Hour Collection __________________________19 Specimen Selection Salivary Assessments A Guide to Choosing Sample Types ________________________________2 Menopause Plus ______________________________________________20 Complete Testing Line Rhythm ____________________________________________________22 Individual Components Breakdown Chart __________________________4 Male Hormones Plus __________________________________________24 One Day Hormone Check ______________________________________26 Therapeutic Ranges for Menopause Profile ________________________28 Profiles -
Circadian Patterns of Plasma Cortisol, 17-Hydroxyprogesterone, and Testosterone in Congenital Adrenal Hyperplasia
Arch Dis Child: first published as 10.1136/adc.56.3.208 on 1 March 1981. Downloaded from Archives of Disease in Childhood, 1981, 56, 208-213 Circadian patterns of plasma cortisol, 17-hydroxyprogesterone, and testosterone in congenital adrenal hyperplasia H FRISCH, K PARTH, EDITH SCHOBER, AND W SWOBODA Department ofPaediatrics, University of Vienna School ofMedicine, andLudwig Boltzman Institutfuir klinische Endokrinologie und Nuklearmedizin, Vienna, Austria SUMMARY In 11 children aged between 2 and 17 years with (nonsalt-losing) congenital adrenal hyperplasia (21-hydroxylase deficiency) blood was drawn at 90-minute intervals during a 24-hour period and levels of 17-hydroxyprogesterone, testosterone, and cortisol were measured. Levels of 1 7-ketosteroids and pregnanetriol were measured too in 24-hour urine samples. These measurements were taken under different regimens of treatment and after interruption of treatment. Cortisol levels rose and fell rapidly after administered corticosteroid, and reached unphysiologically high levels. Testosterone levels showed pronounced variations but stayed in the normal range for most of the time even in untreated patients; thus testosterone provides a poor control parameter. Levels of 1 7-hydroxyprogesterone showed extreme fluctuations and very high peak levels in untreated patients; standard treatment with two or three daily doses of corticosteroids did not prevent a pronounced rise in its level after midnight. After the first morning dose of hydrocortisone a very steep fall was observed. The 24-hour pregnanetriol excretion correlated well with the corresponding total integrated copyright. 1 7-hydroxyprogesterone area. It is concluded that single 1 7-hydroxyprogesterone values are unlikely to give adequate information about the quality oftreatment. -
Sample Report
PATIENT: Sample Report TEST REF: ###-##-##### TEST NUMBER: ########## COLLECTED: dd/mm/yyyy PRACTITIONER: Nordic Laboratories PATIENT NUMBER: ########## RECEIVED: dd/mm/yyyy GENDER: Female TESTED: dd/mm/yyyy ADDRESS: AGE: 28 DATE OF BIRTH: dd-mm-yyyy TEST NAME: Urinary Hormone Metabolites Estrogen Essential Test Name Result Range Urinary Estrogens Estradiol 2.52 H 0.78-1.79 µg/g Cr Premeno-luteal or ERT Estrone 8.58 H 2.27-5.22 µg/g Cr Premeno-luteal or ERT Estriol 2.05 H 0.78-1.98 µg/g Cr Premeno-luteal or ERT E3/(E1+E2) 0.18 L >0.3 (> median value) 2-OH Estradiol 1.23 H 0.17-0.70 µg/g Cr Premeno-luteal or ERT 2-OH Estrone 4.79 H 0.70-2.54 µg/g Cr Premeno-luteal or ERT 4-OH Estradiol 0.35 H 0.10-0.18 µg/g Cr Premeno-luteal or ERT 4-OH Estrone 0.75 H 0.17-0.47 µg/g Cr Premeno-luteal or ERT 16α-OH Estrone 1.00 0.35-1.07 µg/g Cr Premeno-luteal or ERT 2-OH (E1 + E2)/16-α-OH E1 6.02 H 1.29-5.49 Premeno-luteal or ERT 2-MeO Estradiol 0.18 H 0.03-0.08 µg/g Cr Premeno-luteal or ERT 2-MeO Estrone 1.51 H 0.26-0.68 µg/g Cr Premeno-luteal or ERT 2-MeO E1/2-OH E1 0.32 0.21-0.38 Premeno-luteal or ERT 4-MeO Estradiol 0.05 H <0.04 µg/g Cr 4-MeO Estrone 0.04 <0.04 µg/g Cr 4-MeO E1/4-OH E1 0.05 0.05-0.13 Premeno-luteal or ERT 4-MeO E2/4-OH E2 0.14 0.10-0.29 Premeno-luteal or ERT Urinary Creatinine Creatinine (pooled) 0.32 0.3-2.0 mg/mL <dL = Less than the detectable limit of the lab. -
Non-Classic Disorder of Adrenal Steroidogenesis and Clinical Dilemmas in 21-Hydroxylase Deficiency Combined with Backdoor Androg
International Journal of Molecular Sciences Review Non-Classic Disorder of Adrenal Steroidogenesis and Clinical Dilemmas in 21-Hydroxylase Deficiency Combined with Backdoor Androgen Pathway. Mini-Review and Case Report Marta Sumi ´nska 1,* , Klaudia Bogusz-Górna 1, Dominika Wegner 1 and Marta Fichna 2 1 Department of Pediatric Diabetes and Obesity, Poznan University of Medical Sciences, 60-527 Poznan, Poland; [email protected] (K.B.-G.); [email protected] (D.W.) 2 Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, 60-653 Poznan, Poland; mfi[email protected] * Correspondence: [email protected] Received: 3 June 2020; Accepted: 28 June 2020; Published: 29 June 2020 Abstract: Congenital adrenal hyperplasia (CAH) is the most common cause of primary adrenal insufficiency in children and adolescents. It comprises several clinical entities associated with mutations in genes, encoding enzymes involved in cortisol biosynthesis. The mutations lead to considerable (non-classic form) to almost complete (classic form) inhibition of enzymatic activity, reflected by different phenotypes and relevant biochemical alterations. Up to 95% cases of CAH are due to mutations in CYP21A2 gene and subsequent 21α-hydroxylase deficiency, characterized by impaired cortisol synthesis and adrenal androgen excess. In the past two decades an alternative (“backdoor”) pathway of androgens’ synthesis in which 5α-androstanediol, a precursor of the 5α-dihydrotestosterone, is produced from 17α-hydroxyprogesterone, with intermediate products 3α,5α-17OHP and androsterone, in the sequence and with roundabout of testosterone as an intermediate, was reported in some studies. This pathway is not always considered in the clinical assessment of patients with hyperandrogenism. -
Endocrine Test Selection and Interpretation
The Quest Diagnostics Manual Endocrinology Test Selection and Interpretation Fourth Edition The Quest Diagnostics Manual Endocrinology Test Selection and Interpretation Fourth Edition Edited by: Delbert A. Fisher, MD Senior Science Officer Quest Diagnostics Nichols Institute Professor Emeritus, Pediatrics and Medicine UCLA School of Medicine Consulting Editors: Wael Salameh, MD, FACP Medical Director, Endocrinology/Metabolism Quest Diagnostics Nichols Institute San Juan Capistrano, CA Associate Clinical Professor of Medicine, David Geffen School of Medicine at UCLA Richard W. Furlanetto, MD, PhD Medical Director, Endocrinology/Metabolism Quest Diagnostics Nichols Institute Chantilly, VA ©2007 Quest Diagnostics Incorporated. All rights reserved. Fourth Edition Printed in the United States of America Quest, Quest Diagnostics, the associated logo, Nichols Institute, and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics. All third party marks − ®' and ™' − are the property of their respective owners. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, and information storage and retrieval system, without permission in writing from the publisher. Address inquiries to the Medical Information Department, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA 92690-6130. Previous editions copyrighted in 1996, 1998, and 2004. Re-order # IG1984 Forward Quest Diagnostics Nichols Institute has been